Back to results
US 2025/0084104 A1Published application
Heterocyclic compounds as immunomodulators
AssigneeIncyte Corporation
InventorsLiangxing Wu, Kaijiong Xiao, Wenqing Yao
Life of this patent
Estimating the term…
Abstract
Disclosed are compounds of Formula (I), methods of using the compounds as immunomodulators, and pharmaceutical compositions comprising such compounds. The compounds are useful in treating, preventing or ameliorating diseases or disorders such as cancer or infections.
Claims46
A compound of Formula I:
- or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
- R1 is methyl, CN, F, Cl, or Br;
- R2 is methyl, CN, F, Cl, or Br;
- and
- R3 is H, C1-4 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-2 alkyl-, C6-10 aryl, C6-10 aryl-C1-2 alkyl, 5- to 6-membered heteroaryl, 5- to 6-membered heteroaryl-C1-2 alkyl, 4- to 6-membered heterocycloalkyl or 4- to 6-membered heterocycloalkyl-C1-2 alkyl-, wherein the 5- to 6-membered heteroaryl, 5- to 6-membered heteroaryl-C1-2 alkyl, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-2 alkyl- each has one or two heteroatoms as ring members selected from O, N and S, and wherein the C1-4 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-2 alkyl-, C6-10 aryl, C6-10 aryl-C1-2 alkyl, 5- to 6-membered heteroaryl, 5- to 6-membered heteroaryl-C1-2 alkyl, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-2 alkyl- of R3 are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH, OH, CON(CH3)2, CH3, F, Cl, Br, CN, ethyl, and propyl.
2 more elements
A compound of Formula I:
- or a pharmaceutically acceptable salt or a stereoisomer thereof, wherein:
- R1 is methyl, CN, F, Cl, or Br;
- R2 is methyl, CN, F, Cl, or Br;
- and
- R3 is H, C1-4 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-2 alkyl-, C6-10 aryl, C6-10 aryl-C1-2 alkyl, 5- to 6-membered heteroaryl, 5- to 6-membered heteroaryl-C1-2 alkyl, 4- to 6-membered heterocycloalkyl or 4- to 6-membered heterocycloalkyl-C1-2 alkyl-, wherein the 5- to 6-membered heteroaryl, 5- to 6-membered heteroaryl-C1-2 alkyl, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-2 alkyl- each has one or two heteroatoms as ring members selected from O, N and S, and wherein the C1-4 alkyl, C3-8 cycloalkyl, C3-8 cycloalkyl-C1-2 alkyl-, C6-10 aryl, C6-10 aryl-C1-2 alkyl, 5- to 6-membered heteroaryl, 5- to 6-membered heteroaryl-C1-2 alkyl, 4- to 6-membered heterocycloalkyl and 4- to 6-membered heterocycloalkyl-C1-2 alkyl- of R3 are each optionally substituted with 1 or 2 substituents independently selected from CONH2, SO2NH2, COOH, and OH.
2 more elements
Dependencies are inferred from the claim text.